Business Wire

With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?

Share

An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1

‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1

With assisted reproduction therapy, including IVF, already accounting for up to 12% of births in some countries,2,3,4,5 employee expectations are rapidly shifting. 73% of those experiencing fertility challenges say they would be attracted to a role that provides fertility support, reinforcing the need for clearer, more consistent workplace policies.1

A large gap also emerged regarding the impact of going through fertility treatment. While three quarters (75%) of employers feel their organisation acknowledges fertility treatment as a significant life event, only 27% of employees who have experienced fertility challenges agree.1 As a result, more than a fifth (22%) currently felt unsupported by their organisation, rising to 38% in Poland, and more than a third (36%) have felt pressure from their employer to be at work while undergoing treatment or investigations.1

Mental health impact was one of the most consistent themes across all countries. 94% of employees reported that fertility treatment affects their mental wellbeing, with 80% experiencing anxiety or depression during their fertility journey.1

However, the survey did show that practice is starting to change with signs employers recognise the importance of fertility support on employee engagement and talent attraction. 58% either already include fertility and family-building challenges as part of their workforce engagement and wellbeing strategy or will be in the future.1

“At Ferring, we believe that every individual deserves compassionate and practical support during their fertility journey. This research highlights the challenges employees face and reinforces the importance of clear policies, open conversations and workplace cultures that recognise fertility as a significant moment in people’s lives,” said Christelle Beneteau, Chief People Officer, Ferring.

“Fertility treatment is a challenging time, yet the report shows that many people are still navigating it without the support they need, from manager training and awareness, to entitled leave,” said Becky Kearns, Co-Founder of Fertility Matters at Work. “We have seen first-hand how employees who receive fertility support feel more committed to their employer. More workplace recognition and clearer fertility policies could make a huge difference for individuals and organisations, with those who feel supported less likely to leave their jobs.”

“Mental wellbeing and fertility challenges are deeply connected, yet too often overlooked in workplace strategies. This research shows that creating supporting cultures and clear support policies isn’t just compassionate – it’s essential for retaining talent and protecting mental health,” said Kathryn Courtenay-Evans, This Can Happen.

Given that infertility now affects roughly one in six people globally,6 the report makes it clear that workplaces must urgently transform how they support people navigating fertility treatment. This means proactively creating inclusive, open, and supportive cultures, and implementing clear fertility policies to ensure consistent guidance and access to support.

About ‘The Impact of Fertility Challenges at Work: International Insights’ survey

Jointly run by Fertility Matters at Work (FMAW), This Can Happen, and Ferring Pharmaceuticals and funded by Ferring, the survey aims to explore how fertility challenges impact people in the workplace and how employers can offer better support. The survey, of over 3,600 employees and employers, was initially conducted in the UK and has since been rolled out to Australia, Japan, Poland and France.

Report link: The Impact of Fertility Challenges at Work: International Insights

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide.

About Fertility Matters at Work

Fertility Matters at Work is the leading training provider for fertility support in the workplace.

About This Can Happen

This Can Happen is your trusted partner to support mental wellbeing in your workplace.

1 Ferring/Fertility Matters at Work/This Can Happen. 2025. Data on file

2 Newman JE, et al. Assisted reproductive technology in Australia and New Zealand 2022. Available at: https://www.unsw.edu.au/content/dam/pdfs/medicine-health/npesu/research-reports/2024-09-npesu/2024-09-assisted-reproductive-technology-in-australia-and-new-zealand-2022.pdf. Last accessed: November 2025.

3 Centers for Disease Control and Prevention. National ART Surveillance. Available at: https://www.cdc.gov/art/php/surveillance/index.html. Last accessed: November 2025.

4 BBC. Why is IVF so popular in Denmark? Available at: www.bbc.co.uk/news/world-europe-45512312. Last accessed: November 2025.

5 IVIRMA. SEF 2022 Report Data. Available at: http://iviglobaleducation.com/en/12-of-births-in-spain-are-due-to-assisted-reproduction-sef-2022-report-data. Last accessed: November 2025.

6 World Health Organization. Infertility data. Available at: www.who.int/health-topics/infertility#tab=tab_1. Last accessed: November 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20251125104720/en/

Contacts

Matthew Worrall
Director of Corporate Communications, Ferring
+44 7442 271 811
matthew.worrall@ferring.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 02:00:00 EET | Press release

Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade over the duration of the SPA, providing Japan with affordable, reliable American LNG.” About Venture Global Venture Global is an American pro

Airship Study: No-Code Native App Experiences Double Purchase Frequency (+140%), Offering Path to Profitable Holiday Growth26.11.2025 01:08:00 EET | Press release

Mobile-first customer experience company Airship today released new aggregate data analysis findings showing that no-code native app experiences significantly increase conversion for key lifecycle events and more than double purchase frequency. The Airship "Experience Impact” research, which studied over 1,000 in-app retail experiences and 1.7 billion device sessions, quantifies the impact of optimizing end-to-end customer journeys—not just sending messages—using no-code and AI-powered tools to drive loyalty and retention at scale, leading to sustainable profitability in a volatile economic environment. Key Findings Customers exposed to high-impact no-code native app experiences such as optimized onboarding flows, dynamic surveys, or embedded personalized offers, purchase 140% more frequently than app customers who don’t receive them. These experiences, which product owners and marketers can create and adapt without developer resources, significantly increase conversion for key lifecyc

Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 18:30:00 EET | Press release

Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer

Andersen Consulting Bolsters Capabilities with BMA25.11.2025 16:30:00 EET | Press release

Andersen Consulting broadens its sustainability and business transformation capabilities through a Collaboration Agreement with BMA, a South Africa-based firm advancing manufacturing competitiveness and inclusive industrial growth. Established over two decades ago, BMA works across manufacturing value chains—from producers to their clients—alongside government and development agencies to drive sustainable industrial competitiveness. Through its sector-focused industrial clusters, the firm delivers integrated services spanning industrial policy and strategy development, value chain strategy, manufacturing competitiveness and lean consulting, decarbonization and SME development—aligning stakeholders around shared priorities and scalable, long-term solutions. “Sustainable manufacturing goes beyond efficiency. It’s about creating ecosystems that are regenerative, resilient, and strategically aligned with long-term growth,” said Rob Stewart, CEO of BMA. “Many of the organizations we work wi

Pure Lithium Receives Saudi Patent for Vertically Integrated Lithium Metal Battery Technology25.11.2025 15:20:00 EET | Press release

Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the Kingdom of Saudi Arabia has granted the company a foundational patent titled “Vertically Integrated Pure Lithium Metal Production and Lithium Battery Production.” This broad patent covers technology that combines lithium extraction, anode production and battery manufacturing. Pure Lithium’s Brine to Battery™ is a registered trademark in the Kingdom of Saudi Arabia, planting a strong base of intellectual property in the region. “The technology is particularly relevant to Saudi Arabia because it is one of the places in the world with lithium-containing brines, and even has an abundance of vanadium, which is used in our second-generation battery,” said Founder, Chairman and CEO Emilie Bodoin. “In order to displace today’s lithium-ion battery, our vision is to create global battery hubs with closed loop supply chains, not just in the U.S., but in the many places in the world whe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye